PortalPublikationenBosutinib versus imatinib in newly diagnosed chronic-phase c...

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia:results from the 24-month follow-up of the BELA trial

Standard

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia:results from the 24-month follow-up of the BELA trial. / Brümmendorf, Tim H; Cortes, Jorge E; de Souza, Cármino Antonio; Guilhot, Francois; Duvillié, Ladan; Pavlov, Dmitri; Gogat, Karïn; Countouriotis, Athena M; Gambacorti-Passerini, Carlo.

in: BRIT J HAEMATOL, Jahrgang 168, Nr. 1, 2015, S. 69-81.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Brümmendorf, TH, Cortes, JE, de Souza, CA, Guilhot, F, Duvillié, L, Pavlov, D, Gogat, K, Countouriotis, AM & Gambacorti-Passerini, C 2015, 'Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia:results from the 24-month follow-up of the BELA trial', BRIT J HAEMATOL, Jg. 168, Nr. 1, S. 69-81. https://doi.org/10.1111/bjh.13108

APA

Brümmendorf, T. H., Cortes, J. E., de Souza, C. A., Guilhot, F., Duvillié, L., Pavlov, D., Gogat, K., Countouriotis, A. M., & Gambacorti-Passerini, C. (2015). Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia:results from the 24-month follow-up of the BELA trial. BRIT J HAEMATOL, 168(1), 69-81. https://doi.org/10.1111/bjh.13108

Vancouver

Brümmendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvillié L, Pavlov D et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia:results from the 24-month follow-up of the BELA trial. BRIT J HAEMATOL. 2015;168(1):69-81. https://doi.org/10.1111/bjh.13108

Bibtex

@article{6f28f529f9484b13b5b4fb7b679886ef,
title = "Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia:results from the 24-month follow-up of the BELA trial",
abstract = "Bosutinib is an oral, dual SRC/ABL1 tyrosine kinase inhibitor for resistant/intolerant chronic myeloid leukaemia (CML). We assessed the efficacy and safety of bosutinib 500 mg/d (n = 250) versus imatinib 400 mg/d (n = 252) after >24 months from accrual completion in newly diagnosed chronic phase (CP)-CML (Bosutinib Efficacy and Safety in Newly Diagnosed CML trial [BELA]). Cumulative complete cytogenetic response (CCyR) rates by 24 months were similar (bosutinib, 79%; imatinib, 80%); cumulative major molecular response (MMR) rates were 59% for bosutinib and 49% for imatinib. Responses were durable; 151/197 vs. 172/204 and 125/153 vs. 117/131 responders remained on treatment and maintained CCyR and MMR, respectively. Since the 12-month primary analysis, no new accelerated-/blast-phase transformations occurred with bosutinib; four occurred with imatinib. Early response (BCR-ABL1/ABL1 ≤ 10%, 3 months) was associated with better CCyR and MMR rates by 12 and 24 months (both arms). Gastrointestinal events and liver function test elevations were more common, and neutropenia, musculoskeletal events and oedema were less common with bosutinib. Discontinuations due to adverse events were more common with bosutinib versus imatinib (most commonly alanine aminotransferase elevation: 4% vs. <1%); most occurred within the first 12 months. Cardiovascular adverse events were similar in both arms. Bosutinib continues to demonstrate good efficacy and manageable tolerability in newly diagnosed CP-CML patients.",
keywords = "Aged, Aged, 80 and over, Aniline Compounds, Antineoplastic Agents, Benzamides, Female, Follow-Up Studies, Fusion Proteins, bcr-abl, Humans, Leukemia, Myeloid, Chronic-Phase, Male, Middle Aged, Mutation, Nitriles, Odds Ratio, Piperazines, Protein Kinase Inhibitors, Pyrimidines, Quinolines, Treatment Outcome",
author = "Br{\"u}mmendorf, {Tim H} and Cortes, {Jorge E} and {de Souza}, {C{\'a}rmino Antonio} and Francois Guilhot and Ladan Duvilli{\'e} and Dmitri Pavlov and Kar{\"i}n Gogat and Countouriotis, {Athena M} and Carlo Gambacorti-Passerini",
note = "{\textcopyright} 2014 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd.",
year = "2015",
doi = "10.1111/bjh.13108",
language = "English",
volume = "168",
pages = "69--81",
journal = "BRIT J HAEMATOL",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

RIS

TY - JOUR

T1 - Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia:results from the 24-month follow-up of the BELA trial

AU - Brümmendorf, Tim H

AU - Cortes, Jorge E

AU - de Souza, Cármino Antonio

AU - Guilhot, Francois

AU - Duvillié, Ladan

AU - Pavlov, Dmitri

AU - Gogat, Karïn

AU - Countouriotis, Athena M

AU - Gambacorti-Passerini, Carlo

N1 - © 2014 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd.

PY - 2015

Y1 - 2015

N2 - Bosutinib is an oral, dual SRC/ABL1 tyrosine kinase inhibitor for resistant/intolerant chronic myeloid leukaemia (CML). We assessed the efficacy and safety of bosutinib 500 mg/d (n = 250) versus imatinib 400 mg/d (n = 252) after >24 months from accrual completion in newly diagnosed chronic phase (CP)-CML (Bosutinib Efficacy and Safety in Newly Diagnosed CML trial [BELA]). Cumulative complete cytogenetic response (CCyR) rates by 24 months were similar (bosutinib, 79%; imatinib, 80%); cumulative major molecular response (MMR) rates were 59% for bosutinib and 49% for imatinib. Responses were durable; 151/197 vs. 172/204 and 125/153 vs. 117/131 responders remained on treatment and maintained CCyR and MMR, respectively. Since the 12-month primary analysis, no new accelerated-/blast-phase transformations occurred with bosutinib; four occurred with imatinib. Early response (BCR-ABL1/ABL1 ≤ 10%, 3 months) was associated with better CCyR and MMR rates by 12 and 24 months (both arms). Gastrointestinal events and liver function test elevations were more common, and neutropenia, musculoskeletal events and oedema were less common with bosutinib. Discontinuations due to adverse events were more common with bosutinib versus imatinib (most commonly alanine aminotransferase elevation: 4% vs. <1%); most occurred within the first 12 months. Cardiovascular adverse events were similar in both arms. Bosutinib continues to demonstrate good efficacy and manageable tolerability in newly diagnosed CP-CML patients.

AB - Bosutinib is an oral, dual SRC/ABL1 tyrosine kinase inhibitor for resistant/intolerant chronic myeloid leukaemia (CML). We assessed the efficacy and safety of bosutinib 500 mg/d (n = 250) versus imatinib 400 mg/d (n = 252) after >24 months from accrual completion in newly diagnosed chronic phase (CP)-CML (Bosutinib Efficacy and Safety in Newly Diagnosed CML trial [BELA]). Cumulative complete cytogenetic response (CCyR) rates by 24 months were similar (bosutinib, 79%; imatinib, 80%); cumulative major molecular response (MMR) rates were 59% for bosutinib and 49% for imatinib. Responses were durable; 151/197 vs. 172/204 and 125/153 vs. 117/131 responders remained on treatment and maintained CCyR and MMR, respectively. Since the 12-month primary analysis, no new accelerated-/blast-phase transformations occurred with bosutinib; four occurred with imatinib. Early response (BCR-ABL1/ABL1 ≤ 10%, 3 months) was associated with better CCyR and MMR rates by 12 and 24 months (both arms). Gastrointestinal events and liver function test elevations were more common, and neutropenia, musculoskeletal events and oedema were less common with bosutinib. Discontinuations due to adverse events were more common with bosutinib versus imatinib (most commonly alanine aminotransferase elevation: 4% vs. <1%); most occurred within the first 12 months. Cardiovascular adverse events were similar in both arms. Bosutinib continues to demonstrate good efficacy and manageable tolerability in newly diagnosed CP-CML patients.

KW - Aged

KW - Aged, 80 and over

KW - Aniline Compounds

KW - Antineoplastic Agents

KW - Benzamides

KW - Female

KW - Follow-Up Studies

KW - Fusion Proteins, bcr-abl

KW - Humans

KW - Leukemia, Myeloid, Chronic-Phase

KW - Male

KW - Middle Aged

KW - Mutation

KW - Nitriles

KW - Odds Ratio

KW - Piperazines

KW - Protein Kinase Inhibitors

KW - Pyrimidines

KW - Quinolines

KW - Treatment Outcome

U2 - 10.1111/bjh.13108

DO - 10.1111/bjh.13108

M3 - SCORING: Journal article

C2 - 25196702

VL - 168

SP - 69

EP - 81

JO - BRIT J HAEMATOL

JF - BRIT J HAEMATOL

SN - 0007-1048

IS - 1

ER -